Prognosis of Resection and Radiotherapy in the Treatment of Intrahepatic Cholangiocarcinoma Patients
Conditions
Intrahepatic Cholangiocarcinoma
Conditions: official terms
Cholangiocarcinoma - Liver Neoplasms
Conditions: Keywords
Intrahepatic Cholangiocarcinoma, Prognosis, Resection, Radiotherapy
Study Type
Interventional
Study Phase
N/A
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: Resection Type: Procedure
Name: Radiotherapy Type: Radiation
Overall Status
Recruiting
Summary
The purpose of this study is to confirm that prognosis of Intrahepatic Cholangiocarcinoma (ICC) with resection and radiotherapy ,to find which is safe and effective treatment.
Detailed Description
Intrahepatic Cholangiocarcinoma (ICC), the second most common primary liver cancer and constitutes 10% of primary liver malignancies.

Current therapies for the treatment of ICC are ineffective and the role of liver transplantation is not well defined.

This study reviews our experience with this tumor and looks for preoperative and pathologic indices that may help determine long term prognosis
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 60 Years
Minimum Age: 17 Years
Gender: Both
Criteria: Inclusion Criteria:

- Male or female patients > 17 years and <=60 years of age. confirmed case (patients with ICC) Tumors can be radical removed and resection volume was ≤50%. Criteria of liver function: Child A level, serum bilirubin ≤ 1.5 times the upper limit of normal value,alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal value.

No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung function are basically normal. Hbg ≥ 90g/L, WBC ≥ 3.000 cells/mm³,platelets ≥ 80.000 cells/mm³.

Karnofsky Performance Score performance over 60. Patients who can understand this trial and have signed information consent.

Exclusion Criteria:

- Patients who have undergone previous treatment by Resection or Radiotherapy. Patients with apparent cardiac, pulmonary, cerebronic and renal dysfunction, which may affect the treatment of liver cancer.

Patients with other diseases which may affect the treatment mentioned here. Patients with medical history of other malignant tumors. Subjects participating in other clinical trials. Extrahepatic metastasis, portal vein or other major vascular involvement. liver function: Child B C.

Patients would not sign the consent to the trial.
Location
Eastern Hepatobiliary Surgery Hospital
Shanghai, Shanghai, China
Status: Recruiting
Contact: Li Aijun, MD - 86-21-81875531 - ajli62@gmail.com
Start Date
January 2011
Completion Date
April 2016
Sponsors
Eastern Hepatobiliary Surgery Hospital
Source
Eastern Hepatobiliary Surgery Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page